Literature DB >> 13902

The selective action of beta-adrenoceptor blocking drugs and the nature of beta1 and beta2 adrenoceptors.

A J Coleman, A R Somerville.   

Abstract

1 Purified membranes retaining a catecholamine responsive adenylate cyclase have prepared from rabbit heart, lung and (pseudo-pregnant) uterus. 2 These preparations have the characteristics of plasma membranes and both heart and lung respond to beta-adrenoceptor agonists in the order: (+/-)-isoprenaline greater than (-)-noradrenaline greater than (-)-adrenaline greater than (+)-isoprenaline greater than salbutamol. The sensitivity of the adenylate cyclase to beta-adrenoceptor stimulation is improved by pre-treatment of the animals with reserpine and syrosingopine. 3 Dose-ratios for several concentrations of propranolol (non-selective beta-adrenoceptor blocker), practolol and atenolol (cardio-selective beta-adrenoceptor blockers) have been measured on all three membrane preparations. Schild plots of log (dose ratio -1) vs. log dose were virtually coincident for heart and lung with a dissociation constant (Kb) for propranolol very close to the pharmacological value. The ratio of Kb values was 0.65 for practolol and 1.23 for atenolol compared with pharmacological cardio-selectivity ratios (measured on isolated atria and tracheal chain) of 67.6 and 110 respectively. The uterus/heart Kb ratio was 51.5 for atenolol. Inhibition of the uterus by practolol gave a Schild plot with slope significantly less than 1, indicating a different mechanism of action from the heart. 4 Kb values obtained by measuring adenylate cyclase stimulation in chopped tissue (including preparations of bronchial tree and alveolar tissue as well as whole lung) resembled the membrane values rather than those found in whole organs. 5 The results show that the pharmacological selectivity of practolol and atenolol is maintained at the receptor-adenylate cyclase level, at least as far as heart and uterus are concerned, though the smaller selectivity ratios in the biochemical system suggest that receptor differences is not the only factor and that phase distribution of the drug may also be important. Membranes prepared from whole lung show that phase distribution of the drug may also be important. Membranes prepared from whole lung show an overall beta1 response which may simply reflect the predominance of beta1 cell types containing beta1-adrenoceptors over bronchial smooth muscle.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 13902      PMCID: PMC1667712          DOI: 10.1111/j.1476-5381.1977.tb06980.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  16 in total

1.  Drug antagonism and pAx.

Authors:  H O SCHILD
Journal:  Pharmacol Rev       Date:  1957-06       Impact factor: 25.468

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Heterogeneity of adenylate cyclase-coupled beta-adrenergic receptors.

Authors:  R J Lefkowitz
Journal:  Biochem Pharmacol       Date:  1975-03-01       Impact factor: 5.858

4.  K + -stimulated ATPase in purified microsomes of bullfrog oxyntic cells.

Authors:  A L Ganser; J G Forte
Journal:  Biochim Biophys Acta       Date:  1973-04-25

5.  Effects of adrenergic agonists and antagonists on adenylate cyclase activity of dog heart and liver.

Authors:  S E Mayer
Journal:  J Pharmacol Exp Ther       Date:  1972-04       Impact factor: 4.030

6.  A simple and sensitive saturation assay method for the measurement of adenosine 3':5'-cyclic monophosphate.

Authors:  B L Brown; J D Albano; R P Ekins; A M Sgherzi
Journal:  Biochem J       Date:  1971-02       Impact factor: 3.857

7.  Adenyl cyclase and the differentiation of -adrenoreceptors.

Authors:  R A Burges; K J Blackburn
Journal:  Nat New Biol       Date:  1972-02-23

8.  The bronchodilator and cardiac stimulant effects of Thll65a, salbutamol and isoproterenol.

Authors:  R E Giles; J C Williams; M P Finkel
Journal:  J Pharmacol Exp Ther       Date:  1973-09       Impact factor: 4.030

9.  Practolol in treating tachyarrhythmias.

Authors:  J P Van Durme; L Bossaert; P Vermeire; R Pannier
Journal:  Am Heart J       Date:  1973-08       Impact factor: 4.749

10.  Differentiation of receptor systems activated by sympathomimetic amines.

Authors:  A M Lands; A Arnold; J P McAuliff; F P Luduena; T G Brown
Journal:  Nature       Date:  1967-05-06       Impact factor: 49.962

View more
  6 in total

1.  Ethnic differences in human lymphocytic cyclic AMP production after isoprenaline stimulation and propranolol blockade.

Authors:  C P Venter; S Daya; P H Joubert; W J Strydom
Journal:  Br J Clin Pharmacol       Date:  1985-02       Impact factor: 4.335

2.  beta-Adrenoreceptor antagonists in essential tremor.

Authors:  D Jefferson; P Jenner; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-10       Impact factor: 10.154

3.  Biological maturation and beta-adrenergic effectors: development of beta-adrenergic receptors in rabbit heart.

Authors:  W Schumacher; B L Mirkin; J R Sheppard
Journal:  Mol Cell Biochem       Date:  1984       Impact factor: 3.396

Review 4.  Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-06       Impact factor: 9.546

5.  Comparison of four different beta-adrenoceptor blocking drugs on lymphocyte isoprenaline-stimulated cyclic AMP production.

Authors:  D R Lima; S Kilfeather; A Hedges; P Turner
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

6.  Characterization of the receptor mediating the antianaphylactic effects of beta-adrenoceptor agonists in human lung tissue in vitro.

Authors:  P R Butchers; I F Skidmore; C J Vardey; A Wheeldon
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.